T 1095

Drug Profile

T 1095

Alternative Names: RWJ 394718

Latest Information Update: 02 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Johnson & Johnson; Tanabe Seiyaku
  • Class Antihyperglycaemics; Glucosides
  • Mechanism of Action Sodium-glucose transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 12 Jan 2004 Tanabe Seiyaku is switching development to a backup compound
  • 25 Jun 2003 Data presented at the 63rd Scientific Sessions of the American Diabetes Association (ADA-2003) have been added to the Diabetes mellitus pharmacodynamics section
  • 16 Oct 2002 Phase-II clinical trials in Diabetes mellitus in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top